论文部分内容阅读
目的观察升血宝口服液治疗恶性肿瘤放化疗后白细胞减少症的临床疗效。方法将94例患者随机分为2组,治疗组放化疗后口服升血宝口服液,每次20ml,每日3次。对照组放化疗后口服西药升白胺片,每次0.2,每日3次,观察服药前后白细胞(WBC)计数,免疫球蛋白(Ig)及身体状况评分(KPS)的变化。结果治疗组临床有效率87.2%,在升白细胞作用及提高机体免疫功能等方面均优于对照级(P<0.5或P<0.01)。结论升血宝口服液对恶性肿瘤放化疗引起的的白细胞减少症有明显疗效,并能提高机体免疫能力,改善患者生存质量。
Objective To observe the clinical effect of Sheng-Bao-Oral Liquid in the treatment of leucopenia after radiotherapy and chemotherapy of malignant tumor. Methods 94 patients were randomly divided into two groups, the treatment group after oral administration of Sheng Jiang Bao oral solution, each 20ml, 3 times a day. The control group received oral administration of ascending amethicine tablets 0.2 times a day for 3 weeks after radiotherapy and chemotherapy. The changes of white blood cell (WBC) count, immunoglobulin (Ig) and body condition score (KPS) before and after treatment were observed. Results The clinical effective rate was 87.2% in the treatment group, which was better than that in the control group (P <0.5 or P <0.01) in the role of leukocyte and the improvement of immune function. Conclusion Sheng-bao oral liquid on chemotherapy-induced leucopenia have a significant effect, and can improve the body’s immune capacity and improve patient quality of life.